Happy to share my new position: Cardiologist and Assistant Professor of Medicine at the University of Florida College of Medicine-Jacksonville, FL

🩻 CCTA Predicts First Coronary Events — Beyond Risk Scores and Calcium! 💥 Bergström et al., JAMA 2025 🇸🇪 🎯 Goal: To test whether adding��coronary CT angiography (CCTA) findings to traditional risk factors and CAC score (CACS)improves prediction of first coronary events in the

Presented at #AHA25: In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: https://t.co/1LiJFFvnm3 @AHAScience

NEJM, IPD metaanalysis including the totality of evidence of contemporaneous trials (19k patients) confirms NO benefit of Beta-Blockers after MI with Normal Ejection Fraction. just posted online. @RebootTrial https://t.co/GcmC390Xjg

Guess who have completed their fellowship? The rising stars @LuigiSpadafora and @MarcoBernardiMD ☀️☀️

So happy to have found the original article from 1952 that explained the importance of early mobilization in patients with heart attacks (from 6-week bedrest to rapidly moving to a chair has saved millions of lives)

GPX4: Linking Oxidative Stress, Metabolism & Remodeling in Pulmonary Hypertension https://t.co/3WsrFrALf0 @Shuangwang52 #PulmonaryHypertension #Mitochondria #OxidativeStress #Metabolism #CardiovascularResearch

I mean

💉 Intrapericardial Bleomycin: A Promising Option for Malignant Pericardial Effusion https://t.co/vSXkRJVuQl @WaqasHaiderMD #CardioOncology #PericardialEffusion #CancerCare #TargetedTherapy #Pharmacology

Exercise & Resveratrol: Shielding Kidneys and Vessels from Hypertension https://t.co/g5xRNmRxKn #Hypertension #CardiovascularHealth #ExerciseScience #Resveratrol #AgingResearch

🫀 Hidden Plastics, Hidden Risks: Why Phthalates Belong in the Cardio Conversation https://t.co/26LiWnJdhz @gbiondizoccai #CardioToxicity #EnvironmentalHealth #EndocrineDisruptors #Phthalates #PlasticFreeMedicine

🧬 Unlocking Hypertension: Can DNA Methylation Guide Personalized Therapy? https://t.co/8bDfNGxzWT @eryvelton.franco @bernadete.maia @ufpe.oficial @lfpb_ufpe @saudetranslacional @dillanamaral @anderson_corin @31.livia @elainetorres.est @anamavii @andersonmhps @andersonm.rs

Fibroblast Activation Protein: A New Driver of Pulmonary Hypertension https://t.co/TuItqgKuvX #PulmonaryHypertension #Fibrosis #CardiovascularResearch #MolecularPathways #TranslationalMedicine

🌿 Apigenin: A Natural Ally Against Atherosclerosis https://t.co/dZeOUJTiUy #Atherosclerosis #CardiovascularHealth #NaturalCompounds #Apoptosis #DrugDiscovery

Human-Based Tech: The Future of Cardiovascular Pharmacology https://t.co/EKM09iebBq @gbiondizoccai @booz_w #CardiovascularResearch #HumanBasedModels #DrugDiscovery #PrecisionMedicine #Pharmacology

What a privilege to have Prof. ⁦@totocarbone⁩ from ⁦@ODU⁩ ⁦@EVMSMedicine⁩ at ⁦@UVACVRC⁩

In a patient with NSTEMI and multivessel CAD with indication to CABG, is it worth to proceed with bailout urgent PCI?

Anyonw knows why I may have lost all the people I follow? And as you are here feel free to RT our long COVID #COVID consensus document from @escardio https://t.co/757HmQPClX

What a home run! Today the Italian Patent Office has officially granted us the patent for a novel device for left atrial appendage closure! https://t.co/TAC1enq52Y Interested in producing it? Just email me at: giuseppe.biondizoccai@uniroma1.it

Current challenges for the diagnosis of HFpEF and possible simplification of the diagnostic approach, by Marco Bernardi et al https://t.co/5dQsPNbvvo @MarcoBernardiMD